H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Eton Pharmaceuticals (ETON) today and set a price target of $23.00. The company’s shares closed last Monday at $5.32, close to its 52-week low of $5.11.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 18.8% and a 40.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Springworks Therapeutics.
Currently, the analyst consensus on Eton Pharmaceuticals is a Moderate Buy with an average price target of $17.50, implying a 208.1% upside from current levels. In a report issued on March 6, B.Riley FBR also maintained a Buy rating on the stock with a $12.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.20 and a one-year low of $5.11. Currently, Eton Pharmaceuticals has an average volume of 69.84K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. Its portfolio consists of injectable, oral liquid, ophthalmic products pipelines. The company was founded in April 2017 and is headquartered in Deer Park, IL.
